NCT06830343

The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic of SYH9017 in Chinese Participants With Overweight and Obesity Following Single and Multiple Doses

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This is a randomized, double-blind, single-center, dose-escalation, single ascending dose and multiple ascending dose study of SYH9017 in Chinese participants with overweight and obesity.

Conditions

• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	SYH9017	subcutaneous injection once time in SAD and four times in MAD
DRUG	Placebo	subcutaneous injection once time in SAD and four times in MAD
DRUG	Wegovy ®	subcutaneous injection once a week

Timeline

• Start date: 2025-02-27
• Primary completion: 2026-08-01
• Completion: 2026-10-01
• First posted: 2025-02-17
• Last updated: 2026-04-06

Locations

1 site across 1 country: China